Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2024

Open Access 13-02-2024 | Migraine | Review

Influence of metabolic state and body composition on the action of pharmacological treatment of migraine

Authors: Noor Bruijn, Romy van Lohuizen, Malgorzata Boron, Mira Fitzek, Francesca Gabriele, Giada Giuliani, Laura Melgarejo, Pavel Řehulka, Gabriele Sebastianelli, Paul Triller, Simone Vigneri, Behiye Özcan, Antoinette Maassen van den Brink, the European Headache Federation School of Advanced Studies (EHF‐SAS)

Published in: The Journal of Headache and Pain | Issue 1/2024

Login to get access

Abstract

Migraine is a disabling neurovascular disorder among people of all ages, with the highest prevalence in the fertile years, and in women. Migraine impacts the quality of life of affected individuals tremendously and, in addition, it is associated with highly prevalent metabolic diseases, such as obesity, diabetes mellitus and thyroid dysfunction. Also, the clinical response to drugs might be affected in patients with metabolic disease due to body composition and metabolic change. Therefore, the efficacy of antimigraine drugs could be altered in patients with both migraine and metabolic disease. However, knowledge of the pharmacology and the related clinical effects of antimigraine drugs in patients with metabolic disease are limited. Therefore, and given the clinical relevance, this article provides a comprehensive overview of the current research and hypotheses related to the influence of metabolic state and body composition on the action of antimigraine drugs. In addition, the influence of antimigraine drugs on metabolic functioning and, vice versa, the influence of metabolic diseases and its hormonal modulating medication on migraine activity is outlined. Future exploration on personalizing migraine treatment to individual characteristics is necessary to enhance therapeutic strategies, especially given its increasing significance in recent decades.
Literature
1.
Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, Araj-Khodaei M et al (2021) Migraine: a review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol 12:800605PubMedCrossRef
2.
Olesen J (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Vol. 38, Cephalalgia. SAGE Publications Ltd; p. 1–211
3.
Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):954–976CrossRef
4.
5.
Rivera-Mancilla E, Al-Hassany L, Villalón CM, MaassenVanDenBrink A (2021) Metabolic aspects of migraine: association with obesity and diabetes mellitus. Front Neurol 9:12ADS
6.
Tasnim S, Wilson SG, Walsh JP, Nyholt DR, International Headache Genetics Consortium (IHGC) (2023) Shared genetics and causal relationships between migraine and thyroid function traits. Cephalalgia 43(2):03331024221139253.CrossRef
7.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255–323PubMedCrossRef
8.
Dostalek M, Akhlaghi F, Puzanovova M (2012) Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet 51(8):481–499PubMedCrossRef
9.
Smit C, De Hoogd S, Brüggemann RJM, Knibbe CAJ (2018) Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Vol. 14, Expert Opinion on Drug Metabolism and Toxicology. Taylor and Francis Ltd; p. 275–85
10.
Al-Hassany L, Haas J, Piccininni M, Kurth T, Van Den Maassen Brink A, Rohmann JL (2020) Giving researchers a headache - sex and gender differences in migraine. Front Neurol 11:549038PubMedPubMedCentralCrossRef
11.
Kristoffersen ES, Børte S, Hagen K, Zwart JA, Winsvold BS (2020) Migraine, obesity and body fat distribution – a population-based study. J Headache Pain 21(1):97PubMedPubMedCentralCrossRef
12.
Haam J-H, Kim BT, Kim EM, Kwon H, Kang J-H, Park JH et al (2023) Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean society for the study of obesity. J Obes Metab Syndr 32(2):121–129PubMedPubMedCentralCrossRef
13.
Bigal ME, Lipton RB, Holland PR, Goadsby PJ (2007) Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 68(21):1851–1861PubMedCrossRef
14.
Bowman SL, Hudson SA, Simpson G, Munro JF, Clements JA (1986) A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol 21(5):529–532PubMedPubMedCentralCrossRef
15.
Brill MJE, van Rongen A, Houwink API, Burggraaf J, van Ramshorst B, Wiezer RJ et al (2014) Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet 53(10):931–941PubMedPubMedCentralCrossRef
16.
Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87PubMedCrossRef
17.
Yoshinari K, Takagi S, Yoshimasa T, Sugatani J, Miwa M (2006) Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm Res 23(6):1188–1200PubMedCrossRef
18.
Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV et al (2003) CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 38(2):428–435PubMedCrossRef
19.
Abernethy DR, Greenblatt DJ, Divoll M, Shader RI (1983) Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 101(6):873–880PubMed
20.
Manna P, Jain SK (2015) Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies. Metab Syndr Relat Disord 13(10):423–444PubMedPubMedCentralCrossRef
21.
Tong JH, D’Iorio A, Kandaswami C (1979) On the characteristics of mitochondrial monoamine oxidase in pancreas and adipose tissues from genetically obese mice. Can J Biochem 57(3):197–200PubMedCrossRef
22.
Bour S, Daviaud D, Gres S, Lefort C, Prévot D, Zorzano A et al (2007) Adipogenesis-related increase of semicarbazide-sensitive amine oxidase and monoamine oxidase in human adipocytes. Biochimie 89(8):916–925PubMedCrossRef
23.
Visentin V, Prévot D, De Saint Front VD, Morin-Cussac N, Thalamas C, Galitzky J et al (2004) Alteration of amine oxidase activity in the adipose tissue of obese subjects. Obes Res 12(3):547–555PubMedCrossRef
24.
Lloret-Linares C, Luo H, Rouquette A, Labat L, Poitou C, Tordjman J et al (2017) The effect of morbid obesity on morphine glucuronidation. Pharmacol Res 1(118):64–70CrossRef
25.
van der Schoor LW, Verkade HJ, Kuipers F, Jonker JW (2015) New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. Expert Opin Drug Metab Toxicol 11(2):273–293PubMedCrossRef
26.
Aaseth J, Ellefsen S, Alehagen U, Sundfør TM, Alexander J (2021) Diets and drugs for weight loss and health in obesity - An update. Biomed Pharmacother 140:111789PubMedCrossRef
27.
Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA et al (2005) Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 25(3):226–229PubMedCrossRef
28.
Filip M, Bader M (2009) Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol Rep 61(5):761–777PubMedCrossRef
29.
Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6):1259–1287PubMedCrossRef
30.
Akerman S, Romero-Reyes M (2013) Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine. Expert Rev Neurother 13(9):1041–1059PubMedCrossRef
31.
Juhasz G, Zsombok T, Jakab B, Nemeth J, Szolcsanyi J, Bagdy G (2005) Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 25(3):179–183PubMedCrossRef
32.
Gawel MJ, Worthington I, Maggisano A (2001) A systematic review of the use of triptans in acute migraine. Can J Neurol Sci 28(1):30–41PubMedCrossRef
33.
Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS (1991) The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 31(5):291–294PubMedCrossRef
34.
Tfelt-Hansen P, Hougaard A (2013) Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine. Expert Opin Drug Metab Toxicol 9(1):91–103PubMedCrossRef
35.
36.
Jhee SS, Shiovitz T, Crawford AW, Cutler NR (2001) Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 40(3):189–205PubMedCrossRef
37.
Visser WH, de Vriend RH, Jaspers MW, Ferrari MD (1996) Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47(1):46–51PubMedCrossRef
38.
Balbisi EA (2006) Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag 2(3):303–308PubMedPubMedCentralCrossRef
39.
Saracco MG, Allais G, Tullo V, Zava D, Pezzola D, Reggiardo G et al (2014) Efficacy of frovatriptan and other triptans in the treatment of acute migraine of normal weight and obese subjects: a review of randomized studies. Neurol Sci 35(S1):115–119PubMedCrossRef
40.
Munjal S, Gautam A, Rapoport AM, Fisher DM (2016) The effect of weight, body mass index, age, sex, and race on plasma concentrations of subcutaneous sumatriptan: a pooled analysis. Clin Pharmacol 8:109–116PubMedPubMedCentral
41.
Yabut JM, Crane JD, Green AE, Keating DJ, Khan WI, Steinberg GR (2019) Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule. Endocr Rev 40(4):1092–1107PubMedPubMedCentralCrossRef
42.
Rouru J, Pesonen U, Isaksson K, Huupponen R, Koulu M (1993) Effect of chronic treatment with TFMPP, a 5-HT1 receptor agonist, on food intake, weight gain, plasma insulin and neuropeptide mRNA expression in obese Zucker rats. Eur J Pharmacol 234(2–3):191–198PubMedCrossRef
43.
Rolan PE (2012) Drug interactions with triptans : which are clinically significant? CNS Drugs 26(11):949–957PubMedCrossRef
44.
Szkutnik-Fiedler D (2020) Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics 12(12):1180PubMedPubMedCentralCrossRef
45.
Lupi C, Benemei S, Guerzoni S, Pellesi L, Negro A (2019) Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opin Drug Metab Toxicol 15(3):189–198PubMedCrossRef
46.
47.
Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284–294PubMedCrossRef
48.
Kielbasa W, Helton DL (2019) A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia 39(10):1284–1297PubMedPubMedCentralCrossRef
49.
Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH (2010) Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. Clin Pharmacokinet 49:493–507PubMedCrossRef
50.
Roberts BV, Susano I, Gipson DS, Trachtman H, Joy MS (2013) Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease. J Clin Pharmacol 53(9):919–924PubMedCrossRef
51.
Vu T, Ma P, Chen JS, de Hoon J, Van Hecken A, Yan L et al (2017) Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharm Res 34(9):1784–1795PubMedPubMedCentralCrossRef
52.
Barbanti P, Egeo G, Aurilia C, Altamura C, d’Onofrio F, Finocchi C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23(1):138PubMedPubMedCentralCrossRef
53.
Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I et al (2018) Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents. Headache 58(10):1658–69PubMedPubMedCentralCrossRef
54.
Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84(5):548–558PubMedCrossRef
55.
Kuzmiski JB, Barr W, Zamponi GW, MacVicar BA (2005) Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels. Epilepsia 46(4):481–489PubMedCrossRef
56.
Simeone TA, Wilcox KS, White HS (2006) Subunit selectivity of topiramate modulation of heteromeric GABAA receptors. Neuropharmacology 50(7):845–857PubMedCrossRef
57.
Poulsen CF, Simeone TA, Maar TE, Smith-Swintosky V, White HS, Schousboe A (2004) Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons. Neurochem Res 29(1):275–282PubMedCrossRef
58.
59.
Benedetti MS (2000) Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 14(4):301–319PubMedCrossRef
60.
McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR (2007) Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 61(9):1039–1048PubMedCrossRef
61.
Bjørk MH, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K et al (2022) Association of prenatal exposure to Antiseizure medication with risk of autism and intellectual disability. JAMA Neurol 79(7):672–681PubMedCrossRef
62.
Cosentino G, Conrad AO, Uwaifo GI (2013) Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther 7:267–278PubMed
63.
Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U (2003) Predictors of weight loss in adults with Topiramate-treated epilepsy. Obes Res 11(4):556–562PubMedCrossRef
64.
Lowenthal D, Saris SD, Jeffrey P, Alan H, Kathleen C (1984) Mechanisms of action and the clinical pharmacology of beta-adrenergic blocking drugs. Am J Med 5(77):119–127CrossRef
65.
Mehvar R, Brocks DR (2001) Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 4(2):185–200PubMed
66.
Frishman WH, Saunders E (2011) β-Adrenergic blockers. J Clin Hypertens (Greenwich) 13(9):649–653PubMedCrossRef
67.
Kalam MN, Rasool MF, Rehman AU, Ahmed N (2020) Clinical pharmacokinetics of propranolol hydrochloride: a review. Curr Drug Metab 21(2):89–105PubMedCrossRef
68.
Dentali F, Sharma AM, Douketis JD (2005) Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Rep 7(5):330–336PubMedCrossRef
69.
Filser JG, Kaumeier S, Brand T, Schanz H, Terlinden R, Müller WE (1988) Pharmacokinetics of amitriptyline and amitriptylinoxide after intravenous or oral administration in humans. Pharmacopsychiatry 21(6):381–383PubMedCrossRef
70.
Henry JF, Altamura C, Gomeni R, Hervy MP, Forette F, Morselli PL (1981) Pharmacokinetics of amitriptyline in the elderly. Int J Clin Pharmacol 19(1):1–5
71.
McClure EW, Daniels RN (2021) Classics in chemical neuroscience: amitriptyline. ACS Chem Neurosci 12(3):354–362PubMedCrossRef
72.
Cassano GB, Sjöstrand SE, Hansson E (1965) Distribution and fate of C-14-amitriptyline in mice and rats. Psychopharmacologia 8(1):1–11PubMedCrossRef
73.
Nakano S, Hollister LE (1983) Chronopharmacology of amitriptyline. Clin Pharmacol Ther 33(4):453–459PubMedCrossRef
74.
Koh A, Pak KC, Choi HY, Ryu S, Choi SE, Kim KS et al (2019) Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite. Nortriptyline J Clin Pharmacol 59(4):532–540PubMedCrossRef
75.
76.
Dean L (2012) Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype
77.
Puzhko S, Aboushawareb SAE, Kudrina I, Schuster T, Barnett TA, Renoux C et al (2020) Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder. J Affect Disord 267:153–170PubMedCrossRef
78.
Young WB (2008) Preventive treatment of migraine: Effect on weight. Curr Pain Headache Rep 12(3):201–206PubMedCrossRef
79.
Berilgen MS, Bulut S, Gonen M, Tekatas A, Dag E, Mungen B (2005) Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 25(11):1048–1053PubMedCrossRef
80.
Caproni S, Corbelli I, Pini LA, Cupini ML, Calabresi P, Sarchielli P (2011) Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: the results of a pilot study. Cephalalgia 31(5):543–549PubMedCrossRef
81.
Di Vincenzo A, Beghetto M, Vettor R, Tana C, Rossato M, Bond DS et al (2020) Effects of surgical and non-surgical weight loss on migraine headache: a systematic review and meta-analysis. Obes Surg 30(6):2173–2185PubMedCrossRef
82.
Afshinmajd S, Davati A, Akbari F (2011) The effects of body mass index on the treatment of the patients with migraine headaches. Iran J Neurol 10(3–4):35–38PubMedPubMedCentral
83.
Rainero I, Limone P, Ferrero M, Valfrè W, Pelissetto C, Rubino E et al (2005) Insulin sensitivity is impaired in patients with migraine. Cephalalgia 25(8):593–597PubMedCrossRef
84.
Cavestro C, Rosatello A, Micca G, Ravotto M, Marino MP, Asteggiano G et al (2007) Insulin metabolism is altered in migraineurs: a new pathogenic mechanism for migraine? Headache 47(10):1436–1442PubMedCrossRef
85.
McCarthy LC, Hosford DA, Riley JH, Bird MI, White NJ, Hewett DR et al (2001) Single-Nucleotide Polymorphism Alleles in the Insulin Receptor Gene Are Associated with Typical Migraine. Genomics 78(3):135–149PubMedCrossRef
86.
Wang LH, Zhou SX, Li RC, Zheng LR, Zhu JH, Hu SJ et al (2012) Serum levels of calcitonin gene-related peptide and substance P are decreased in patients with diabetes mellitus and coronary artery disease. J Int Med Res 40(1):134–140PubMedCrossRef
87.
Berge LI, Riise T, Fasmer OB, Hundal O, Oedegaard KJ, Midthjell K et al (2013) Does diabetes have a protective effect on migraine? Epidemiology 24:129–134PubMedCrossRef
88.
Antonazzo IC, Riise T, Cortese M, Berge LI, Engeland A, Fasmer OB et al (2018) Diabetes is associated with decreased migraine risk: a nationwide cohort study. Cephalgia 38:1759–64CrossRef
89.
Aamodt AH, Stovner LJ, Midthjell K, Hagen K, Zwart JA (2007) Headache prevalence related to diabetes mellitus. The Head-HUNT study. Eur J Neurol 14(7):738–744PubMedCrossRef
90.
Fagherazzi G, El Fatouhi D, Fournier A, Gusto G, Mancini FR, Balkau B et al (2019) Associations between migraine and type 2 diabetes in women: findings from the E3N cohort study. JAMA Neurol 76(3):257–263PubMedCrossRef
91.
Haghighi FS, Rahmanian M, Namiranian N, Arzaghi SM, Dehghan F, Chavoshzade F et al (2015) Migraine and type 2 diabetes; is there any association? J Diabetes Metab Disord 15(1):37PubMedCrossRef
92.
Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M et al (2010) Migraine and cardiovascular disease: s population-based study. Neurology 74(8):628–635PubMedPubMedCentralCrossRef
93.
Del Moro L, Rota E, Pirovano E, Rainero I (2022) Migraine, Brain Glucose Metabolism and the “Neuroenergetic” Hypothesis: a scoping review. J Pain 23(8):1294–1317PubMedCrossRef
94.
Hosseinpour M, Maleki F, Khoramdad M, Sullman MJM, Nejadghaderi SA, Kolahi AA et al (2021) A systematic literature review of observational studies of the bilateral association between diabetes and migraine. Diabetes Metab Syndr 15(3):673–678PubMedCrossRef
95.
Hagen K, Åsvold BO, Midthjell K, Stovner LJ, Zwart JA, Linde M (2018) Inverse relationship between type 1 diabetes mellitus and migraine. Data from the Nord-Trøndelag Health Surveys 1995–1997 and 2006–2008. Cephalalgia 38(3):417–26PubMedCrossRef
96.
Horowitz M, Wishart JM, Jones KL, Hebbard GS (1996) Gastric emptying in diabetes: an overview. Diabet Med 13(9 Suppl 5):S16-22PubMed
97.
Triantafyllou K, Kalantzis C, Papadopoulos AA, Apostolopoulos P, Rokkas T, Kalantzis N et al (2007) Video-capsule endoscopy gastric and small bowel transit time and completeness of the examination in patients with diabetes mellitus. Dig Liver Dis 39(6):575–580PubMedCrossRef
98.
Marangos MN, Skoutelis AT, Nightingale CH, Zhu Z, Psyrogiannis AG, Nicolau DP et al (1995) Absorption of ciprofloxacin in patients with diabetic gastroparesis. Antimicrob Agents Chemother 39(9):2161–2163PubMedPubMedCentralCrossRef
99.
Häggendal E, Steen B, Svanborg A (1970) Blood flow in subcutaneous fat tissue in patients with diabetes mellitus. Acta Med Scand 187(1–2):49–53PubMedCrossRef
100.
Dimitriadis G, Lambadiari V, Mitrou P, Maratou E, Boutati E, Panagiotakos DB et al (2007) Impaired postprandial blood flow in adipose tissue may be an early marker of insulin resistance in type 2 diabetes. Diabetes Care 30(12):3128–3130PubMedCrossRef
101.
Nosadini R, De Kreutzenberg S, Duner E, Iori E, Avogaro A, Trevisan R et al (1988) Porcine and human insulin absorption from subcutaneous tissues in normal and insulin-dependent diabetic subjects: a deconvolution-based approach. J Clin Endocrinol Metab 67(3):551–559PubMedCrossRef
102.
Moore EW, Mitchell ML, Chalmers TC (1959) Variability in absorption of insulin-I 131 in normal and diabetic subjects after subcutaneous and intramuscular injection. J Clin Invest 38(7):1222–1227PubMedPubMedCentralCrossRef
103.
Bonadonna RC, Groop L, Kraemer N, Ferrannini E, Del Prato S, DeFronzo RA (1990) Obesity and insulin resistance in humans: a dose-response study. Metabolism 39(5):452–459PubMedCrossRef
104.
Day JF, Thorpe SR, Baynes JW (1979) Nonenzymatically glucosylated albumin. In vitro preparation and isolation from normal human serum. J Biol Chem 254(3):595–7PubMedCrossRef
105.
Ruiz-Cabello F, Erill S (1984) Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 36(5):691–695PubMedCrossRef
106.
McNamara PJ, Blouin RA, Brazzell RK (1988) The protein binding of phenytoin, propranolol, diazepam, and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res 5(5):261–265PubMedCrossRef
107.
Gatti G, Crema F, Attardo-Parrinello G, Fratino P, Aguzzi F, Perucca E (1987) Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 9(4):389–391PubMedCrossRef
108.
Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G (1994) Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19(3):616–627PubMedCrossRef
109.
Darakjian L, Deodhar M, Turgeon J, Michaud V (2021) Chronic inflammatory status observed in patients with type 2 diabetes induces modulation of cytochrome P450 expression and activity. Int J Mol Sci 22(9):4967PubMedPubMedCentralCrossRef
110.
Lee JH, Yang SH, Oh JM, Lee MG (2010) Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 62(1):1–23PubMedCrossRef
111.
Sotaniemi EA, Pelkonen O, Arranto AJ, Tapanainen P, Rautio A, Pasanen M (2002) Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 90(3):155–160PubMedCrossRef
112.
Pucci L, Chirulli V, Marini S, Lucchesi D, Penno G, Gervasi PG et al (2005) Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals. Pharmacol Res 51(6):561–565PubMedCrossRef
113.
Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC (2003) Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55(1):77–85PubMedPubMedCentralCrossRef
114.
Adithan C, Sriram G, Swaminathan RP, Krishnan M, Bapna JS, Chandrasekar S (1989) Effect of type II diabetes mellitus on theophylline elimination. Int J Clin Pharmacol 27(5):258–260
115.
Marques MP, Coelho EB, Dos Santos NAG, Geleilete TJM, Lanchote VL (2002) Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 58(9):607–614PubMedCrossRef
116.
Kvitne KE, Åsberg A, Johnson LK, Wegler C, Hertel JK, Artursson P et al (2022) Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity. Clin Transl Sci 15(11):2685–2696PubMedPubMedCentralCrossRef
117.
118.
Dinçer Y, Alademir Z, Ilkova H, Akçay T (2002) Susceptibility of glutatione and glutathione-related antioxidant activity to hydrogen peroxide in patients with type 2 diabetes: effect of glycemic control. Clin Biochem 35(4):297–301PubMedCrossRef
119.
Zhou H, Tan KCB, Shiu SWM, Wong Y (2008) Determinants of leukocyte adenosine triphosphate-binding cassette transporter G1 gene expression in type 2 diabetes mellitus. Metabolism 57(8):1135–1140PubMedCrossRef
120.
Sasso FC, De Nicola L, Carbonara O, Nasti R, Minutolo R, Salvatore T et al (2006) Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care 29(3):498–503PubMedCrossRef
121.
Meeme A, Kasozi H (2009) Effect of glycaemic control on glomerular filtration rate in diabetes mellitus patients. Afr Health Sci 9 Suppl 1(Suppl 1):S23-6PubMed
122.
García G, de Vidal EL, Trujillo H (1977) Serum levels and urinary concentrations of kanamicin, bekanamicin and amikacin (BB-K8) in diabetic children and a control group. J Int Med Res 5(5):322–329PubMedCrossRef
123.
Madácsy L, Bokor M, Matusovits L (1975) Penicillin clearance in diabetic children. Acta Paediatr Acad Sci Hung 16(2):139–142PubMed
124.
Trovik TS, Jaeger R, Jorde R, Sager G (1994) Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness. Br J Clin Pharmacol 38(5):427–432PubMedPubMedCentralCrossRef
125.
126.
Berlin I, Grimaldi A, Landault C, Zoghbi F, Thervet F, Puech AJ et al (1988) Lack of hypoglycemic symptoms and decreased beta-adrenergic sensitivity in insulin-dependent diabetic patients. J Clin Endocrinol Metab 66(2):273–278PubMedCrossRef
127.
de OliveiraSouza C, Sun X, Oh D (2021) Metabolic Functions of G Protein-Coupled Receptors and β-Arrestin-Mediated Signaling Pathways in the Pathophysiology of Type 2 Diabetes and Obesity. Front Endocrinol (Lausanne) 12:715877CrossRef
128.
Clissold S, Edwards C (1988) Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:214–43PubMedCrossRef
129.
Infante M, Leoni M, Caprio M, Fabbri A (2021) Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World J Diabetes 12:916–31PubMedPubMedCentralCrossRef
130.
Hsu WH, Hsiao PJ, Lin PC, Che SC, Lee MY, Shin SJ (2017) Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease. Oncotarget 17:5416–5423
131.
Scheen A (2007) Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 46:93–108PubMedCrossRef
132.
Smith U (2001) Pioglitazone: mechanism of action. Int J Clin Pract Suppl 121:13–18
133.
Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE (2020) The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev 41(5):733–755PubMedPubMedCentralCrossRef
134.
Polidori DC, Bergman RN, Chung ST, Sumner AE (2016) Hepatic and extrahepatic insulin clearance are differentially regulated: Results from a novel model-based. Diabetes 65(6):1556–1564PubMedPubMedCentralCrossRef
135.
Levien TL, Baker DE, White JR, Campbell RK (2002) Insulin glargine: a new basal insulin. Ann Pharmacother 36(6):1019–1027PubMedCrossRef
136.
Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123(7):612–624PubMedPubMedCentralCrossRef
137.
138.
Coulie B, Tack J, Bouillon R, Peeters T, Janssens J (1998) 5-Hydroxytryptamine-1 receptor activation inhibits endocrine pancreatic secretion in humans. Am J Physiol 274(2):E317–E320PubMed
139.
Golubic R, Hussein Ismail M, Josipovic M, Kennet J, Galderisi A, Evans ML (2023) Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: a double-blinded placebo-controlled cross-over trial. Diabetes Obes Metab 25(10):3059–3063PubMedCrossRef
140.
Labastida-Ramírez A, Rubio-Beltrán E, Haanes KA, Chan KY, Garrelds IM, Johnson KW et al (2020) Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain 161(5):1092–1099PubMedPubMedCentralCrossRef
141.
Sonne N, Karsdal MA, Henriksen K (2021) Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases. Mol Metab 46:101109PubMedCrossRef
142.
Ghanizada H, Al-Karagholi MAM, Walker CS, Arngrim N, Rees T, Petersen J et al (2021) Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients. Ann Neurol 89(6):1157–1171PubMedPubMedCentralCrossRef
143.
Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099–1142PubMedPubMedCentralCrossRef
144.
Halloran J, Lalande A, Zang M, Chodavarapu H, Riera CE (2020) Monoclonal therapy against calcitonin gene-related peptide lowers hyperglycemia and adiposity in type 2 diabetes mouse models. Metabol Open 8:100060PubMedPubMedCentralCrossRef
145.
146.
Paravattil B, Wilby KJ, Turgeon R (2016) Topiramate monotherapy for weight reduction in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 114:9–14PubMedCrossRef
147.
Khanna V, Arumugam S, Roy S, Mittra S, Bansal VS (2008) Topiramate and type 2 diabetes: an old wine in a new bottle. Expert Opin Ther Targets 12(1):81–90PubMedCrossRef
148.
Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y (2000) Influence of Topiramate in the Regulation of Energy Balance. Nutrition 16:961–966PubMedCrossRef
149.
Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F et al (2007) Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Int J Obes 31(1):138–146CrossRef
150.
Raffaelli B, García-Azorín D, Boucherie DM, Amin FM, Deligianni CI, Gil-Gouveia R et al (2023) European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention - part 3: topiramate. J Headache Pain 24(1):134PubMedPubMedCentralCrossRef
151.
Manitpisitkul P, Curtin CR, Shalayda K, Wang SS, Ford L, Heald D (2014) Pharmacokinetic interactions between topiramate and pioglitazone and metformin. Epilepsy Res 108(9):1519–1532PubMedCrossRef
152.
Mills GA, Horn JR (1985) Beta-blockers and glucose control. Drug Intell Clin Pharm 19(4):246–251PubMed
153.
Dunne F, Kendall MJ, Martin U (2001) Beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus: is there a role? Drugs 61(4):429–435PubMedCrossRef
154.
Tuncay E, Zeydanli EN, Turan B (2011) Cardioprotective effect of propranolol on diabetes-induced altered intracellular Ca2+ signaling in rat. J Bioenerg Biomembr 43(6):747–756PubMedCrossRef
155.
Blaufarb I, Pfeifer T, Frishman W (1995) beta-blockers. Drug interactions of clinical significance. Drug Saf 13:359–70PubMedCrossRef
156.
Joseph Haas S, Pharm B, Pharm Sci B, Vos T, Gilbert RE, Krum H et al (2003) Are-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146(5):848–853CrossRef
157.
Lu Z, Li Y, Syn WK, Wang Z, Lopes-Virella MF, Lyons TJ et al (2020) Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism. Am J Physiol Endocrinol Metab 318(2):E131–E144PubMedCrossRef
158.
Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M (2006) Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 67(12):1856–1861PubMedCrossRef
159.
Chadwick W, Wilson G, van de Venter M, Oelofsen W, Roux S (2010) Shifts in metabolic parameters surrounding glucose homoeostasis resulting from tricyclic antidepressant therapy: implications of insulin resistance? J Pharm Pharmacol 59(1):95–103CrossRef
160.
161.
Tasnim S, Nyholt DR (2023) Migraine and thyroid dysfunction: Co-occurrence, shared genes and biological mechanisms. Eur J Neurol 30(6):1815–1827PubMedCrossRef
162.
Rovet JF (2014) The role of thyroid hormones for brain development and cognitive function. Endocr Dev 26:26–43PubMedCrossRef
163.
Le H, Tfelt-Hansen P, Russell MB, Skytthe A, Kyvik KO, Olesen J (2011) Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia 31(1):43–64PubMedCrossRef
164.
Martin AT, Pinney SM, Xie C, Herrick RL, Bai Y, Buckholz J et al (2017) Headache disorders may be a risk factor for the development of new onset hypothyroidism. Headache 57(1):21–30PubMedCrossRef
165.
Abou Elmaaty AA, Flifel ME, Belal T, Zarad CA (2020) Migraine and tension headache comorbidity with hypothyroidism in Egypt. Egypt J Neurol Psychiatr Neurosurg 56(1):78CrossRef
166.
Bougea A, Spantideas N, Anagnostou E, Voskou P, Katsika P, Evdokimidis I et al (2017) Efficacy of levothyroxine in migraine patients with subclinical hypothyroidism. Eur J Neurol 24(Supp. 1):19–122
167.
Dev P, Favas TT, Jaiswal RK, Cyriac M, Mishra VN, Pathak A (2023) The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebo-controlled trial. Cephalalgia 43(10):3331024231182684PubMedCrossRef
168.
Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA (2019) Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol 18(8):795–804PubMedPubMedCentralCrossRef
169.
170.
Thomas FB, Caldwell JH, Greenberger NJ (1973) Steatorrhea in thyrotoxicosis. Relation to hypermotility and excessive dietary fat. Ann Intern Med 78(5):669–75PubMedCrossRef
171.
Aro A, Anttila M, Korhonen T, Sundquist H (1982) Pharmacokinetics of propranolol and sotalol in hyperthyroidism. Eur J Clin Pharmacol 21(5):373–377PubMedCrossRef
172.
Misra GC, Bose SL, Samal AK (1991) Malabsorption in thyroid dysfunctions. J Indian Med Assoc 89(7):195–197PubMed
173.
Burk O, Brenner SS, Hofmann U, Tegude H, Igel S, Schwab M et al (2010) The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin. Clin Pharmacol Ther 88(5):685–694PubMedCrossRef
174.
175.
Vargas F, Moreno JM, Rodríguez-Gómez I, Wangensteen R, Osuna A, Alvarez-Guerra M et al (2006) Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 154(2):197–212PubMedCrossRef
176.
Liddle C, Goodwin BJ, George J, Tapner M, Farrell GC (1998) Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab 83(7):2411–2416PubMed
177.
Takahashi N, Inui N, Morita H, Takeuchi K, Uchida S, Watanabe H et al (2010) Effect of thyroid hormone on the activity of CYP3A enzyme in humans. J Clin Pharmacol 50(1):88–93PubMedCrossRef
178.
179.
Egashira T, Yamanaka Y (1987) Changes in MAO activities in several organs of rats after administration of l-thyroxine. Jpn J Pharmacol 45(2):135–142PubMedCrossRef
180.
Cabanillas AM, Masini-Repiso AM, Coleoni AH (1991) Rat thyroid monoamine oxidase (MAO) is regulated by thyrotrophin: Evidence that the main form of the enzyme (MAO-A) is not directly involved in iodide organification. J Endocrinol 131(1):25–31PubMedCrossRef
181.
Park YJ, Lee EK, Lee YK, Park DJ, Jang HC, Moore DD (2012) Opposing regulation of cytochrome P450 expression by CAR and PXR in hypothyroid mice. Toxicol Appl Pharmacol 263(2):131–137PubMedPubMedCentralCrossRef
182.
Hallengren B, Nilsson OR, Karlberg BE, Melander A, Tegler L, Wåhlin-Boll E (1982) Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol. Eur J Clin Pharmacol 21(5):379–384PubMedCrossRef
183.
LeBoff MS, Kaplan MM, Silva JE, Larsen PR (1982) Bioavailability of thyroid hormones from oral replacement preparations. Metabolism 31(9):900–905PubMedCrossRef
184.
Bartalena L, Robbins J (1992) Variations in thyroid hormone transport proteins and their clinical implications. Thyroid 2(3):237–245PubMedCrossRef
185.
Engler D, Burger AG (1984) The deiodination of the iodothyronines and of their derivatives in man. Endocr Rev 5(2):151–184PubMedCrossRef
186.
Crooks J, Hedley AJ, Macnee C, Stevenson IH (1973) Proceedings: Changes in drug metabolizing ability in thyroid disease. Br J Pharmacol 49(1):156–157
187.
Sarlis NJ, Gourgiotis L (2005) Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics. Curr Drug Targets Immune Endocr Metabol Disord 5(4):439–448PubMedCrossRef
188.
Bagchi N, Brown TR, Mack RE (1978) Studies on the mechanism of inhibition of thyroid function by lithium. Biochim Biophys Acta 542(1):163–169PubMedCrossRef
189.
Trip MD, Wiersinga W, Plomp TA (1991) Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 91(5):507–511PubMedCrossRef
190.
Oppenheimer JH, Bernstein G, Surks MI (1968) Increased thyroxine turnover and thyroidal function after stimulation of hepatocellular binding of thyroxine by phenobarbital. J Clin Invest 47(6):1399–1406PubMedPubMedCentralCrossRef
191.
Isley WL (1987) Effect of rifampin therapy on thyroid function tests in a hypothyroid patient on replacement L-thyroxine. Ann Intern Med 107(4):517–518PubMedCrossRef
192.
Sahajpal R, Ahmed RA, Hughes CA, Foisy MM (2017) Probable interaction between levothyroxine and ritonavir: case report and literature review. Am J Health Syst Pharm 74(8):587–592PubMedCrossRef
193.
van der Spek AH, Fliers E, Boelen A (2017) Thyroid hormone metabolism in innate immune cells. J Endocrinol 232(2):R67-81PubMedCrossRef
194.
Shih FY, Chuang YC, Chuang MJ, Lu YT, Tsai WC, Fu TY et al (2017) Effects of antiepileptic drugs on thyroid hormone function in epilepsy patients. Seizure 48:7–10PubMedCrossRef
195.
Adhimoolam M, Arulmozhi R (2016) Effect of antiepileptic drug therapy on thyroid hormones among adult epileptic patients: An analytical cross-sectional study. J Res Pharm Pract 5(3):171–174PubMedPubMedCentralCrossRef
196.
Han Y, Yang J, Zhong R, Guo X, Cai M, Lin W (2022) Side effects of long-term oral anti-seizure drugs on thyroid hormones in patients with epilepsy: a systematic review and network meta-analysis. Neurol Sci 43(9):5217–5227PubMedCrossRef
197.
198.
Obi MF, Namireddy V, Garg Y, Sharma M (2023) Benefit and Preference of Propranolol Over Metoprolol in Thyrotoxicosis-Induced Atrial Fibrillation: a case report and review of literature. Cureus 15(1):e34474PubMedPubMedCentral
199.
Franklyn J, Wilkins M, Wilkinson R, Ramsden DB, Sheppard MC (1985) The effect of propranolol on circulating thyroid hormone measurements in thyrotoxic and euthyroid subjects. Acta Endocrinol (Copenh) 108:351–355PubMed
200.
Wiersinga W, Van Noorden CJ, Touber JL (1979) Propranolol inhibits the in vitro conversion of thyroxine into triiodothyronine by isolated rat liver parenchymal cells. Horm Metab Res 11:366–370PubMedCrossRef
201.
Levey GS (1976) The adrenergic nervous system in hyperthyroidism: therapeutic role of beta adrenergic blocking drugs. Pharmacolo Ther Part C: Clin Pharmacol Ther 1(3–4):431–43
202.
Levitt MA, Sullivan JB, Owens SM, Burnham L, Finley PR (1986) Amitriptyline plasma protein binding: effect of plasma pH and relevance to clinical overdose. Am J Emerg Med 4(2):121–125PubMedCrossRef
203.
Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J (2019) The metabolic face of migraine - from pathophysiology to treatment. Nat Rev Neurol 15(11):627–643PubMedCrossRef
Metadata
Title
Influence of metabolic state and body composition on the action of pharmacological treatment of migraine
Authors
Noor Bruijn
Romy van Lohuizen
Malgorzata Boron
Mira Fitzek
Francesca Gabriele
Giada Giuliani
Laura Melgarejo
Pavel Řehulka
Gabriele Sebastianelli
Paul Triller
Simone Vigneri
Behiye Özcan
Antoinette Maassen van den Brink
the European Headache Federation School of Advanced Studies (EHF‐SAS)
Publication date
13-02-2024
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2024
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-024-01724-3

Other articles of this Issue 1/2024

The Journal of Headache and Pain 1/2024 Go to the issue

Research

Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat

Research

AMPK activation attenuates central sensitization in a recurrent nitroglycerin-induced chronic migraine mouse model by promoting microglial M2-type polarization

Research

Specific cognitive and psychological alterations are more strongly linked to increased migraine disability than chronic migraine diagnosis

Research

Healthcare utilisation and economic burden of migraines among bank employees in China: a probabilistic modelling study

Research

Aberrant cerebral blood flow and functional connectivity in patients with vestibular migraine: a resting-state ASL and fMRI study

Research

Increased CX3CL1 in cerebrospinal fluid and ictal serum t-tau elevations in migraine: results from a cross-sectional exploratory case-control study
Image Credits